 ATLANTA--BUSINESS WIRE--Virios Therapeutics, Inc. Nasdaq: VIRI, a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that clinical data was highlighted in an oral presentation at Digestive Disease Week DDW 2021, the premier global meeting for physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal 